Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Small Cell Lung Carcinoma 576Breast Neoplasms 419Neoplasms 299Adenocarcinoma of Lung 249Colorectal Neoplasms 222Melanoma 201Mesothelioma, Malignant 183Pancreatic Neoplasms 179Prostatic Neoplasms 178Brain Neoplasms 178Head and Neck Neoplasms 173Neoplasm Metastasis 167Ovarian Neoplasms 153Esophageal Neoplasms 152Mesothelioma 145Colonic Neoplasms 140Stomach Neoplasms 139NSCLC 115Pleural Effusion, Malignant 114Carcinoma, Renal Cell 109Urinary Bladder Neoplasms 105Disease 96Sarcoma 85Uterine Cervical Neoplasms 82Thymoma 79Liver Neoplasms 77Motor Activity 75Squamous Cell Carcinoma of Head and Neck 72

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × High-Risk Resectable NSCLC × Thoracic × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡